This course has expired. View available courses.
Cardiovascular, Medication Management
Elecsys proBNP II and the evolving role of NT-proBNP testing in the diagnosis of heart failure
N-terminal pro B-type natriuretic peptide (NT-proBNP) has demonstrated diagnostic and prognostic value in heart failure (HF). Clinical guidelines, including those of the National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand, recommend measuring NT-proBNP in patients with suspected acute or chronic HF, when the diagnosis is uncertain, in order to expedite […]
DURATION
15 min
PROFESSION
Specialist
# OF CREDITS
0
ACCREDITATION
Unaccredited
EXPIRY DATE
2023-02-15
N-terminal pro B-type natriuretic peptide (NT-proBNP) has demonstrated diagnostic and prognostic value in heart failure (HF). Clinical guidelines, including those of the National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand, recommend measuring NT-proBNP in patients with suspected acute or chronic HF, when the diagnosis is uncertain, in order to expedite either early diagnosis or early exclusion of HF. Very high NT-proBNP concentration carries a poor prognosis and changes in NT-proBNP correlate with clinical course, facilitating individualised clinical management.
This educational activity was developed by MdBriefCase, with funding from Roche Diagnostics.
Faculty
Professor Andrew Sindone, B. Med (Hons), MD, FRACP, FCSANZ, FNHFA
Learning objectives
After reading this product brief, cardiologists should improve their:
- Appreciation of the diagnostic value of NT-pro BNP testing in acute and chronic HF
- Recognition of the prognostic role of NT-proBNP concentrations in a variety of clinical scenarios
- Understanding of the role of NT-pro BNP testing in optimising discharge planning of patients with HF